In a filing, Cardiff Oncology Inc revealed its Director PACE GARY W acquired Company’s shares for reported $41100.0 on Dec 19 ’23. In the deal valued at $1.37 per share,30,000 shares were bought. As a result of this transaction, PACE GARY W now holds 697,761 shares worth roughly $1.88 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
William Blair initiated its Cardiff Oncology Inc [CRDF] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. H.C. Wainwright started covering the stock on October 22, 2020. It rated CRDF as “a Buy”.
Price Performance Review of CRDF
On Friday, Cardiff Oncology Inc [NASDAQ:CRDF] saw its stock fall -4.59% to $2.70. Over the last five days, the stock has lost -7.85%. Cardiff Oncology Inc shares have risen nearly 82.43% since the year began. Nevertheless, the stocks have risen 69.81% over the past one year. While a 52-week high of $6.42 was reached on 03/25/24, a 52-week low of $0.94 was recorded on 02/05/24. SMA at 50 days reached $3.88, while 200 days put it at $2.46. A total of 0.57 million shares were traded, compared to the trading of 0.41 million shares in the previous session.
Levels Of Support And Resistance For CRDF Stock
The 24-hour chart illustrates a support level at 2.59, which if violated will result in even more drops to 2.47. On the upside, there is a resistance level at 2.82. A further resistance level may holdings at 2.93. The Relative Strength Index (RSI) on the 14-day chart is 25.22, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.19, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.06%. Stochastics %K at 18.27% indicates the stock is a buying.
The most recent change occurred on October 08, 2020 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $25 price target.
